Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology ; day:30 ; month:8 ; year:2020 ; pages:1-12
Drug safety ; (30.8.2020), 1-12
- Urheber
-
Tavares-Da-Silva, Fernanda
Mahaux, Olivia
Holle, Lionel Van
Haguinet, François
Seifert, Harry
Stegmann, Jens-Ulrich
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40264-020-00989-2
- URN
-
urn:nbn:de:101:1-2020101722401972034328
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tavares-Da-Silva, Fernanda
- Mahaux, Olivia
- Holle, Lionel Van
- Haguinet, François
- Seifert, Harry
- Stegmann, Jens-Ulrich
- SpringerLink (Online service)
Ähnliche Objekte (12)
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance